Paid Clinical Trials in Knoxville, TN

As of June 2026, 230 paid clinical trials are recruiting in Knoxville, Tennessee. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.

Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 8, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

230 clinical trials

↓ Download CSV

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

211 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554406·Phase 2·Recruiting

Apply to this trial

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

for Refractory or Unexplained Chronic Cough

69 locations incl. Foley

Sponsor: Nocion Therapeutics

Sex: All·Age: 18 - 80

Code: NCT06504446·Phase 2·Recruiting

Apply to this trial

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

for Migraine

Drug: Ubrogepant

103 locations incl. Birmingham

Sponsor: AbbVie

Sex: Female·Age: 18+

Code: NCT06417775·Phase 3·Recruiting

Apply to this trial

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

for Melanoma

104 locations incl. Chandler

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06246916·Phase 3·Recruiting

Apply to this trial

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

for Multiple Myeloma

50 locations incl. Gilbert

Sponsor: Kite, A Gilead Company

Sex: All·Age: 18+

Code: NCT06413498·Phase 3·Recruiting

Apply to this trial

Strategic and Interactive Signing Instruction

for Teaching Behaviors

1 location in Knoxville

Sponsor: The University of Tennessee, Knoxville

Sex: All·Age: 4 - 99

Code: NCT06667102·Enrolling By Invitation

A Study to Evaluate Solrikitug in Participants With COPD (ZION)

for COPD

101 locations incl. Birmingham

Sponsor: Uniquity One (UNI)

Sex: All·Age: 40 - 75

Code: NCT06496620·Phase 2·Recruiting

Apply to this trial

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

for Hepatocellular Carcinoma

12 locations incl. Beverly Hills

Sponsor: Replimune, Inc.

Sex: All·Age: 18+

Code: NCT05733598·Phase 2·Recruiting

Apply to this trial

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

for Relapsing Multiple Sclerosis

87 locations incl. Birmingham

Sponsor: TG Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06433752·Recruiting

Apply to this trial

Daily Eating Patterns for Total Health Study

for Obesity

1 location in Knoxville

Sponsor: The University of Tennessee, Knoxville

Sex: All·Age: 25 - 60

Code: NCT06455995·Recruiting

Apply to this trial

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

for Advanced Melanoma

Drug: Nivolumab

50 locations incl. Gilbert

Sponsor: Replimune, Inc.

Sex: All·Age: 12+

Code: NCT06264180·Phase 3·Recruiting

Apply to this trial

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

for Cardiovascular Risk

Drug: Ziltivekimab

208 locations incl. Alexander City

Sponsor: Novo Nordisk A/S

Sex: All·Age: 18+

Code: NCT06118281·Phase 3·Recruiting

Apply to this trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for Acute Myeloid Leukemia

335 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05564390·Phase 2·Recruiting

Apply to this trial

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

for Advanced Melanoma

Drug: Nivolumab

37 locations incl. Tucson

Sponsor: Immunocore Ltd

Sex: All·Age: 18+

Code: NCT06112314·Phase 3·Recruiting

Apply to this trial

A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

for Hypothyroidism

134 locations incl. Birmingham

Sponsor: AbbVie

Sex: All·Age: 18 - 75

Code: NCT06345339·Phase 2, Phase 3·Recruiting

Apply to this trial

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

for Ganglioneuroblastoma, Nodular

156 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 30

Code: NCT06172296·Phase 3·Recruiting

Apply to this trial

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

for Non-Muscle Invasive Bladder Neoplasms

38 locations incl. Little Rock

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06319820·Phase 3·Recruiting

Apply to this trial

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

for Heart Failure and Impaired Kidney Function

Drug: Dapagliflozin

166 locations incl. Alexander City

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT06307652·Phase 3·Recruiting

Apply to this trial

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

for Non-Small Cell Lung Cancer

Drug: Rilvegostomig

63 locations incl. Anchorage

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06357533·Phase 3·Recruiting

Apply to this trial

Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence

for Diabetes

2 locations incl. Knoxville

Sponsor: University of Tennessee

Sex: All·Age: 18+

Code: NCT06374277·Recruiting

Apply to this trial

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

for Non Small Cell Lung Cancer

49 locations incl. Little Rock

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312137·Phase 3·Recruiting

Apply to this trial

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

for Prostate Cancer

44 locations incl. Homewood

Sponsor: Curium US LLC

Sex: Male·Age: 18+

Code: NCT06235151·Phase 3·Recruiting

Apply to this trial

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

for Immunoglobulin A Nephropathy

46 locations incl. Alabaster

Sponsor: Alexion Pharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT06291376·Phase 3·Recruiting

Apply to this trial

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

for Recurrent Langerhans Cell Histiocytosis

104 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 180 Days - 22

Code: NCT05828069·Phase 2·Recruiting

Apply to this trial

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

for Diabetes Mellitus, Type 2

124 locations incl. Chandler

Sponsor: Cleerly, Inc.

Sex: All·Age: 55+·Accepts healthy volunteers

Code: NCT06112418·Recruiting

Apply to this trial

Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)

for Alzheimer Disease

53 locations incl. Phoenix

Sponsor: Cognito Therapeutics, Inc.

Sex: All·Age: 50 - 92

Code: NCT06245031·Enrolling By Invitation

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

for Emphysema, Pulmonary

18 locations incl. Phoenix

Sponsor: Pulmonx Corporation

Sex: All·Age: 40 - 80

Code: NCT06035120·Recruiting

Apply to this trial

The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis

for Myasthenia Gravis

11 locations incl. Aurora

Sponsor: Ad scientiam

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT05564936·Recruiting

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

Drug: LY3537982

91 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting

Apply to this trial

Evaluation of Radiobiological Effects in Skin Toxicities Head and Neck Cancer Patients With PBS Proton Therapy

for Head and Neck Cancer

1 location in Knoxville

Sponsor: Covenant Health Cancer Center

Sex: All·Age: 18+

Code: NCT06183268·Recruiting

Apply to this trial

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

for Non-small Cell Lung Cancer

Drug: Intismeran autogene

68 locations incl. Anchorage

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06077760·Phase 3·Recruiting

Apply to this trial

Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators

for COPD (Chronic Obstructive Pulmonary Disease)

1 location in Knoxville

Sponsor: University of Tennessee Graduate School of Medicine

Sex: All·Age: 40+

Code: NCT07133880·Phase 4·Recruiting

Apply to this trial

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

for B Acute Lymphoblastic Leukemia Associated With Down Syndrome

69 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 6 - 39

Code: NCT05702645·Recruiting

Apply to this trial

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for Anatomic Stage II Breast Cancer AJCC v8

Drug: Durvalumab

535 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06058377·Phase 3·Recruiting

Apply to this trial

The PEERLESS II Study

for Pulmonary Embolism

50 locations incl. Birmingham

Sponsor: Inari Medical

Sex: All·Age: 18+

Code: NCT06055920·Recruiting

Apply to this trial

Transvaginal Detrusor Nerve Radiofrequency Ablation for Treatment of Overactive Bladder

for Overactive Bladder Syndrome

2 locations incl. Corona del Mar

Sponsor: InMode MD Ltd.

Sex: Female·Age: 21 - 80

Code: NCT06283498·Enrolling By Invitation

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

for Neovascular Age-related Macular Degeneration

63 locations incl. Glendale

Sponsor: Jaeb Center for Health Research

Sex: All·Age: 50+

Code: NCT05904028·Phase 3·Recruiting

Apply to this trial

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

for Progressive Pulmonary Fibrosis

70 locations incl. Birmingham

Sponsor: United Therapeutics

Sex: All·Age: 18+

Code: NCT05943535·Phase 3·Recruiting

Apply to this trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1208 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting

Apply to this trial

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

for Breast Cancer, Early Breast Cancer

Drug: Camizestrant

148 locations incl. Dothan

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT05952557·Phase 3·Recruiting

Apply to this trial